Participants 14 51 6
AMSA in children with acute leukemia.
Participants 87 394 7
One hundred four children with advanced leukemia in relapse (74 with acute lymphocytic leukemia [ALL] and 30 with acute nonlymphocytic leukemia [ANLL]) received AMSA (4'-(9-Acridinylamino) methanesulfon -m-anisidide) at a dose of 120 mg/m2/day for 5 days (Regimen I) or 60 mg/m2/day for 10 days (Regimen II)
Participants 502 537 4
All 29 evaluable patients with ANLL
